Advancing Drug Development by Reducing Reliance on Animal Testing.
Case Example: Pre-Clinical Animal Models in Lung Toxicology.
Aer Therapeutics, a biopharmaceutical company developing novel inhaled treatments for mucus-associated lung disease, is presenting at a workshop titled “Advancing Drug Development by Reducing Reliance on Animal Testing. Case Example: Pre-Clinical Animal Models in Lung Toxicology”. The meeting aims to examine historic value, limitations and translatability of animal models in pulmonary drug development, to assess the impact of today’s regulatory environment on product development in respiratory space, and to propose human-relevant alternatives to animal testing that will help advance new therapies in this space. The goals of this meeting align with the broad priorities of the FDA to minimize animal testing in drug development.
All meeting materials, including meeting recording, transcripts and slides, are available on Reagan-Udall Foundation website.
